What is your preferred neoadjuvant chemotherapy (FOLFIRINOX vs gemcitabine/nab-paclitaxel) and duration for a resectable T2N1 pancreatic adenocarcinoma in a fit patient whose surgery has been cancelled due to COVID-19 risk in the hospital?
Answer from: Medical Oncologist at Academic Institution
We treat resectable pancreatic patients with neoadjuvant therapy regardless. In a fit patient, we will recommend starting with FOLFIRINOX chemotherapy. Restaging scans should be fine every 2 months. We could consider therapy for 4-6 months.
Comments
Medical Oncologist at Novant Health Oncology Specialists What would be recommended for patients not fit eno...
Medical Oncologist at Mayo Clinic In the neoadjuvant setting where FOLFIRINOX is not...
Medical Oncologist at Novant Health Oncology Specialists Thank you! Greatly helpful! Since Gem Abraxane has...
What would be recommended for patients not fit eno...
In the neoadjuvant setting where FOLFIRINOX is not...
Thank you! Greatly helpful! Since Gem Abraxane has...